J&J wins approval of Varipulse atrial fibrillation device

Medical form with words Atrial fibrillation (AFib).

designer491

  • The U.S. FDA has approved Johnson & Johnson MedTech’s (NYSE:JNJ) Varipulse, a device to treat drug refractory paroxysmal atrial fibrillation.
  • The Varipulse platform combines pulsed field ablation therapy and advanced mapping with the Carto 3 system, a 3D electroanatomical cardiac mapping

Leave a Reply

Your email address will not be published. Required fields are marked *